Entresto has not gone generic in the United States as of late 2023. The drug, a combination of sacubitril and valsartan, is marketed by Novartis and is still protected by patents.
When Does Entresto Lose Patent Protection?
The primary patents protecting Entresto are set to expire in 2027. However, the exact date of patent expiry can be complex due to various patent filings and potential extensions. DrugPatentWatch.com tracks these patent timelines, indicating that exclusivity for Entresto is anticipated to end around 2027, with some sources suggesting later dates due to additional patents [1].
What Happens After Entresto's Patents Expire?
Once Entresto's patents expire, generic manufacturers will be able to produce and sell their own versions of the drug. This typically leads to a significant decrease in the drug's price due to increased competition. The availability of generic alternatives usually allows more patients to access the medication.
Can Biosimilars Be Developed for Entresto?
Entresto is a small molecule drug, not a biologic. Therefore, biosimilars, which are similar versions of biologic drugs, are not applicable. Instead, generic versions of Entresto can be developed.
Who Are Entresto's Main Competitors?
While Entresto is a novel combination therapy, other medications are used to treat heart failure, including ACE inhibitors, ARBs, and beta-blockers. These serve as alternative treatment options for patients, though Entresto has demonstrated superior outcomes in clinical trials for certain patient populations [2].
What Are the Clinical Trial Results for Entresto?
The PARADIGM-HF trial, a pivotal study for Entresto, showed that the drug significantly reduced cardiovascular death and heart failure hospitalizations compared to enalapril, an ACE inhibitor, in patients with symptomatic chronic heart failure with reduced ejection fraction [2]. This trial was instrumental in its approval and widespread adoption.
What Are the Risks Associated with Entresto?
Common side effects of Entresto include hypotension, hyperkalemia, cough, dizziness, and renal impairment. More serious risks can include angioedema and fetal toxicity [3]. Patients should discuss potential risks and side effects with their healthcare providers.
How Is Entresto Priced?
Currently, Entresto is a branded medication with a significant cost. The price can vary based on insurance coverage, pharmacy, and dosage. The introduction of generic versions after patent expiry is expected to lower these costs considerably.
*
**Sources:
1. DrugPatentWatch.com
2. Nature Medicine
3. FDA